VolitionRx’s (VNRX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of VolitionRx (NYSE:VNRX) in a report released on Friday,Benzinga reports. D. Boral Capital currently has a $3.00 price target on the stock.

Several other research analysts also recently commented on the company. Maxim Group downgraded VolitionRx from a “buy” rating to a “hold” rating in a report on Wednesday, December 3rd. HC Wainwright decreased their price objective on VolitionRx from $2.50 to $1.50 and set a “buy” rating for the company in a report on Monday, November 17th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $2.50.

VolitionRx Price Performance

Shares of VNRX stock opened at $0.33 on Friday. The company has a market capitalization of $40.89 million, a P/E ratio of -0.92 and a beta of 1.23. The company’s 50-day simple moving average is $0.31 and its two-hundred day simple moving average is $0.52. VolitionRx has a one year low of $0.22 and a one year high of $0.94.

Insider Activity

In related news, Director Guy Archibald Innes acquired 96,153 shares of the firm’s stock in a transaction that occurred on Tuesday, October 14th. The stock was purchased at an average cost of $0.51 per share, with a total value of $49,038.03. Following the transaction, the director directly owned 1,062,967 shares of the company’s stock, valued at $542,113.17. This trade represents a 9.95% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Cameron John Reynolds bought 110,000 shares of the stock in a transaction that occurred on Tuesday, October 14th. The stock was bought at an average price of $0.51 per share, with a total value of $56,100.00. Following the completion of the purchase, the chief executive officer directly owned 2,534,847 shares in the company, valued at $1,292,771.97. This represents a 4.54% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders acquired 274,229 shares of company stock valued at $136,657. Corporate insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

A number of large investors have recently bought and sold shares of VNRX. Armistice Capital LLC increased its holdings in VolitionRx by 10.4% in the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the company’s stock worth $6,367,000 after buying an additional 887,351 shares during the period. Lagoda Investment Management L.P. boosted its holdings in shares of VolitionRx by 6.7% in the 3rd quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the company’s stock valued at $8,476,000 after acquiring an additional 782,000 shares during the last quarter. Citadel Advisors LLC increased its stake in shares of VolitionRx by 70.1% in the third quarter. Citadel Advisors LLC now owns 329,520 shares of the company’s stock worth $224,000 after acquiring an additional 135,775 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new position in shares of VolitionRx during the second quarter worth $52,000. Finally, Silverberg Bernstein Capital Management LLC lifted its position in VolitionRx by 42.8% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company’s stock valued at $153,000 after purchasing an additional 60,209 shares during the period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx NV is a multi-national in vitro diagnostics company focused on the development and commercialization of novel blood-based tests for the detection and monitoring of cancer and other diseases. The company’s proprietary Nucleosomics® technology leverages epigenetic and structural changes in nucleosomes—fragments of DNA wrapped around histone proteins—to identify disease-specific biomarkers in blood samples. VolitionRx’s primary goal is to offer simple, minimally invasive tests that facilitate early detection and improve patient outcomes.

VolitionRx’s product pipeline centers on the Nu.Q® family of immunoassays, which are designed to measure concentrations and modifications of circulating nucleosomes.